{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:41:12Z","timestamp":1790314872299,"version":"4.1.0"},"reference-count":188,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":323,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with an estimated incidence of 0.7\u20132 cases per million\/year. The rarity of this disease, coupled with limited preclinical models and clinical trials, has hindered progress, resulting in poor outcomes, with a 5-year survival rate of approximately 35%. Currently, the only available curative treatment is complete surgical resection of the adrenal tumor. For unresectable or metastatic ACC, the current standard therapeutic modalities are mitotane, chemotherapy, radiotherapy and locoregional treatments; however, these are noncurative. Mitotane has an adrenolytic and anti-steroidogenic effect, and it is used in the adjuvant setting for high-risk patients, as systemic therapy for metastatic disease, and\/or to control hormonal secretion. While key pathways in ACC pathogenesis have been identified as potential therapeutic targets, results with targeted therapies remain modest, showing that there is a clinical unmet need for novel treatments or new combinations of exiting drugs. Effective management requires a multidisciplinary team of experts to optimize outcomes for patients. This article presents a multidisciplinary consensus on the diagnosis, management, prognosis and follow-up of patients with ACC, and the approach to two special contexts, ACC in pregnant women and hormone-producing ACC. The consensus was coordinated by the Spanish Society of Endocrinology and Nutrition (SEEN) and the Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE), with contribution from experts from related societies including the Spanish Association of Surgeons (AEC), Spanish Society of Urology (AEU), Anatomic-Pathology (SEAP), Nuclear Medicine (SEMNIM), Medical Oncology (SEOM) and Radiotherapeutic Oncology (SEOR).<\/jats:p>","DOI":"10.1530\/erc-25-0034","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T13:47:18Z","timestamp":1744379238000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":6,"title":["Spanish consensus on the diagnosis and management of adrenocortical carcinoma"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":true,"given":"Marta","family":"Araujo-Castro","sequence":"first","affiliation":[{"name":"Endocrinology & Nutrition Department. Hospital Universitario Ram\u00f3n y Cajal Madrid 1 , ,","place":["Madrid, Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica Ram\u00f3n y Cajal (IRYCIS) 2 , ,","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4448-7941","authenticated-orcid":true,"given":"Cristina","family":"\u00c1lvarez-Escola","sequence":"additional","affiliation":[{"name":"Endocrinology & Nutrition Department. Hospital Universitario La Paz 3 , ,","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Caster\u00e0s","sequence":"additional","affiliation":[{"name":"Endocrinology & Nutrition Department. Hospital Universitario Vall d\u00b4Hebron 4 , ,","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Carmona-Bayonas","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB 5 , ,","place":["Murcia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Dolores","family":"Chiara","sequence":"additional","affiliation":[{"name":"Health Research Institute of the Principality of Asturias, Oviedo, Spain 6"},{"name":"Institute of Oncology of the Principality of Asturias, University of Oviedo 7 , ,","place":["Oviedo, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia A","family":"Hanzu","sequence":"additional","affiliation":[{"name":"Endocrinology & Nutrition Department, Hospital Clinic, University of Barcelona, IDIBPAS, CIBERDEM 8 , ,","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hernando","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Hospital Universitario Vall D'Hebron, Vall Hebron Institute of Oncology (VHIO) 9 , ,","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L","family":"Vercher-Conejero","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Hospital Universitario de Bellvitge, IDIBELL, 10 ,","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Rodr\u00edguez-Fraile","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Cl\u00ednica Universidad de Navarra 11 , ,","place":["Navarra, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"G\u00f3mez Dos Santos","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica Ram\u00f3n y Cajal (IRYCIS) 2 , ,","place":["Madrid, Spain"]},{"name":"Urology Department, Hospital Universitario Ram\u00f3n y Cajal Madrid 12 , ,","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA 13 , ,","place":["Oviedo, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Giraldo","sequence":"additional","affiliation":[{"name":"Radiotherapy Oncology Department, Hospital Universitario Vall D' Hebron, VHIO 14 , ,","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Vald\u00e9s","sequence":"additional","affiliation":[{"name":"Endocrinology & Nutrition Department, Hospital Universitario Cruces 15 , ,","place":["Barakaldo, Spain"]},{"name":"UPV\/EHU, Biobizkaia, CIBERDEM, CIBERER, Endo-ERN 16 , ,","place":["Barakaldo, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Vidal","sequence":"additional","affiliation":[{"name":"General Surgery Department. Hospital Clinic de Barcelona 17 , ,","place":["Barcelona, Spain"]},{"name":"University of Barcelona 18 , ,","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Del Olmo-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Endocrinology & Nutrition Department. Hospital Universitario y Polit\u00e9cnico La Fe 19 , ,","place":["Valencia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8017-9941","authenticated-orcid":true,"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Hospital Universitario Vall D'Hebron, Vall Hebron Institute of Oncology (VHIO) 9 , ,","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"2026070905473546700_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1530\/EJE-10-0412","article-title":"Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis","volume":"163","author":"Abiven-Lepage","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib2","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/jc.2005-2730","article-title":"Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients","volume":"91","author":"Abiven","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib3","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/cncr.10487","article-title":"A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist","volume":"94","author":"Abraham","year":"2002","journal-title":"Cancer"},{"key":"2026070905473546700_bib4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00261-019-02371-y","article-title":"Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management","volume":"45","author":"Ahmed","year":"2020","journal-title":"Abdom Radiol"},{"key":"2026070905473546700_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.amjsurg.2020.10.038","article-title":"Analysis of adjuvant chemotherapy in patients undergoing curative-intent resection of localized adrenocortical carcinoma","volume":"222","author":"Al Asadi","year":"2021","journal-title":"Am J Surg"},{"key":"2026070905473546700_bib6","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2005-2639","article-title":"Clinical review: adrenocortical carcinoma: clinical update","volume":"91","author":"Allolio","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib7","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1245\/s10434-018-6398-5","article-title":"Impact of micro- and macroscopically positive surgical margins on survival after resection of adrenocortical carcinoma","volume":"25","author":"Anderson","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2026070905473546700_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.endinu.2019.01.004","article-title":"SEEN guidelines for the management and prevention of acute adrenal insufficiency","volume":"67","author":"Araujo Castro","year":"2019","journal-title":"Endocrinologia, Diabetes y Nutricion"},{"key":"2026070905473546700_bib9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.endinu.2020.03.002","article-title":"Practical guide on the initial evaluation, follow-up, and treatment of adrenal incidentalomas Adrenal Diseases Group of the Spanish Society of Endocrinology and Nutrition","volume":"67","author":"Araujo-Castro","year":"2020","journal-title":"Endocrinol Diabetes Nutr"},{"key":"2026070905473546700_bib10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/biomedicines9030304","article-title":"Immunotherapy in adrenocortical carcinoma: predictors of response, efficacy, safety, and mechanisms of resistance","volume":"9","author":"Araujo-Castro","year":"2021","journal-title":"Biomedicines"},{"key":"2026070905473546700_bib11","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1210\/jc.2011-1565","article-title":"Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors","volume":"96","author":"Arlt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"},{"key":"2026070905473546700_bib13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/jpm11040269","article-title":"What is the optimal duration of adjuvant mitotane therapy in adrenocortical carcinoma? An unanswered question","volume":"11","author":"Basile","year":"2021","journal-title":"J Personalized Med"},{"key":"2026070905473546700_bib14","first-page":"186","article-title":"Pregnancy in a patient with adrenocortical carcinoma during treatment with mitotane \u2013 a case report","volume":"62","author":"Baszko-B\u0142aszyk","year":"2011","journal-title":"Endokrynol Pol"},{"key":"2026070905473546700_bib15","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/annonc\/mdf291","article-title":"Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma","volume":"13","author":"Baudin","year":"2002","journal-title":"Ann Oncol"},{"key":"2026070905473546700_bib16","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1200\/JCO.2022.40.16_suppl.4596","article-title":"EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): preliminary results of the SPENCER study","volume":"40","author":"Baudin","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026070905473546700_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-20-0205","article-title":"HIF2\u03b1 supports pro-metastatic behavior in pheochromocytomas\/paragangliomas","volume":"27","author":"Bechmann","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"2026070905473546700_bib18","doi-asserted-by":"crossref","first-page":"e001009","DOI":"10.1136\/jitc-2020-001009","article-title":"Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma","volume":"8","author":"Bedrose","year":"2020","journal-title":"J ImmunoTherapy Cancer"},{"key":"2026070905473546700_bib19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2013.11.006","article-title":"Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer","volume":"65","author":"Berruti","year":"2014","journal-title":"Eur Urol"},{"key":"2026070905473546700_bib20","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1210\/jc.2004-1267","article-title":"Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation","volume":"90","author":"Betz","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib22","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"2026070905473546700_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/106689690401200304","article-title":"Adrenocortical oncocytic tumors: report of 10 cases and review of the literature","volume":"12","author":"Bisceglia","year":"2004","journal-title":"Int J Surg Pathol"},{"key":"2026070905473546700_bib24","doi-asserted-by":"crossref","first-page":"E4698","DOI":"10.1210\/clinem\/dgab449","article-title":"Combination of mitotane and locoregional treatments in low-volume metastatic adrenocortical carcinoma","volume":"106","author":"Boil\u00e8ve","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-22-0208","article-title":"Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients","volume":"187","author":"Bonnet-Serrano","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib26","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1038\/s41388-020-1358-5","article-title":"Wnt\/\u03b2-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice","volume":"39","author":"Borges","year":"2020","journal-title":"Oncogene"},{"key":"2026070905473546700_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/jmg.2008.057570","article-title":"Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families","volume":"45","author":"Bougeard","year":"2008","journal-title":"J Med Genet"},{"key":"2026070905473546700_bib28","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1148\/radiol.2433051978","article-title":"Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses","volume":"243","author":"Byung","year":"2007","journal-title":"Radiology"},{"key":"2026070905473546700_bib29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/EJE-18-0923","article-title":"Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence","volume":"180","author":"Calabrese","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/ejendo\/lvad002","article-title":"The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients","volume":"188","author":"Calabrese","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(24)00095-0","article-title":"Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial","volume":"25","author":"Campbell","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026070905473546700_bib32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11060-024-04670-x","article-title":"Medical treatment of functional pituitary adenomas, trials and tribulations","volume":"168","author":"Capatina","year":"2024","journal-title":"J Neuro Oncol"},{"key":"2026070905473546700_bib33","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaf082","article-title":"Does adjuvant mitotane impact cure rates in adrenocortical carcinoma? Insights from the ICARO-GETTHI\/SEEN registry","author":"Carmona-Bayonas","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib34","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib35","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1210\/clinem\/dgab122","article-title":"Approach to the patient treated with steroidogenesis inhibitors","volume":"106","author":"Castinetti","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib36","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jvir.2010.05.020","article-title":"Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma","volume":"21","author":"Cazejust","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"2026070905473546700_bib37","first-page":"669","article-title":"Adrenocortical cancer update","volume":"94","author":"Chagpar","year":"2014","journal-title":"Surg Clin"},{"key":"2026070905473546700_bib38","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1097\/RLU.0000000000004563","article-title":"68 Ga-DOTA.SA.FAPI as a potential, noninvasive diagnostic probe for recurrent and metastatic adrenocortical carcinoma: a head-to-head comparison with 18F-FDG","volume":"48","author":"Chopra","year":"2023","journal-title":"Clin Nucl Med"},{"key":"2026070905473546700_bib39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2012-2851","article-title":"Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5\u03b1-reductase, explaining the need for personalized glucocorticoid and androgen replacement","volume":"98","author":"Chortis","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2012-2851","article-title":"Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5\u03b1-reductase, explaining the need for personalized glucocorticoid and androgen replacement","volume":"98","author":"Chortis","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib41","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1210\/clinem\/dgz141","article-title":"Urine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma","volume":"105","author":"Chortis","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib42","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s00464-013-3034-0","article-title":"Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?","volume":"27","author":"Cooper","year":"2013","journal-title":"Surg Endosc"},{"key":"2026070905473546700_bib43","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/EJE-19-0570","article-title":"Activity and safety of temozolomide in advanced adrenocortical carcinoma patients","volume":"181","author":"Cosentini","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib44","doi-asserted-by":"crossref","first-page":"11523","DOI":"10.1200\/JCO.2022.40.16_suppl.11523","article-title":"Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor","volume":"40","author":"Cranmer","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026070905473546700_bib45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.soc.2015.08.011","article-title":"Surgical management of adrenocortical carcinoma: an evidence-based approach","volume":"25","author":"Datta","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"key":"2026070905473546700_bib46","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1210\/jc.2015-2341","article-title":"Pregnancy in women previously treated for an adrenocortical carcinoma","volume":"100","author":"de Corbi\u00e8re","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/CCO.0000000000000695","article-title":"Adrenocortical carcinoma: current treatment options","volume":"33","author":"De Filpo","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"2026070905473546700_bib48","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.surg.2024.09.008","article-title":"Which lymphadenectomy for adrenocortical carcinoma?","volume":"176","author":"de Ponthaud","year":"2024","journal-title":"Surgery"},{"key":"2026070905473546700_bib49","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/oncolo\/oyae084","article-title":"A review of mitotane in the management of adrenocortical cancer","volume":"29","author":"Del Rivero","year":"2024","journal-title":"Oncologist"},{"key":"2026070905473546700_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.903545","article-title":"Metyrapone versus osilodrostat in the short-term therapy of endogenous cushing\u2019s syndrome: results from a single center cohort study","volume":"13","author":"Detomas","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026070905473546700_bib51","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1245\/s10434-018-6749-2","article-title":"Evaluation, staging, and surgical management for adrenocortical carcinoma: an update from the SSO endocrine and head and neck disease site working group","volume":"25","author":"Dickson","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2026070905473546700_bib52","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1245\/s10434-013-3164-6","article-title":"Long-term survival after adrenalectomy for stage I\/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of laparoscopic versus open approach","volume":"21","author":"Donatini","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2026070905473546700_bib53","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00259-023-06547-z","article-title":"CXCR4-directed PET\/CT with [68 Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathology","volume":"51","author":"Dreher","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070905473546700_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1530\/EJE-21-0510","article-title":"S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study","volume":"186","author":"Elhassan","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib55","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2013-2856","article-title":"Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma","volume":"99","author":"Else","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/jc.2012-2559","article-title":"The role of surgery in the management of recurrent adrenocortical carcinoma","volume":"98","author":"Erdogan","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib57","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.3390\/ijms21228529","article-title":"Tyrosine kinase receptors in oncology","volume":"21","author":"Esteban-Villarrubia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026070905473546700_bib58","doi-asserted-by":"crossref","first-page":"R249","DOI":"10.1530\/EJE-15-1118","article-title":"The genomics of adrenocortical tumors","volume":"174","author":"Faillot","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib59","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/HJH.0000000000003252","article-title":"Diagnosis and management of hypertension in patients with Cushing\u2019s syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"40","author":"Fallo","year":"2022","journal-title":"J Hypertens"},{"key":"2026070905473546700_bib60","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1210\/jc.2006-1007","article-title":"Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma","volume":"91","author":"Fassnacht","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib188","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"key":"2026070905473546700_bib61","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1210\/jc.2010-0803","article-title":"Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers","volume":"95","author":"Fassnacht","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib62","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: a clinician\u2019s update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"2026070905473546700_bib63","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"2026070905473546700_bib64","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026070905473546700_bib65","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib66","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"key":"2026070905473546700_bib67","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"key":"2026070905473546700_bib68","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2022.12.006","article-title":"Corrigendum to \u201cAdrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up\u201d: [Annals of Oncology volume 31 (2020) 1476\u20131490]","volume":"34","author":"Fassnacht","year":"2023","journal-title":"Ann Oncol"},{"key":"2026070905473546700_bib69","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"189","author":"Fassnacht","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(24)00378-4","article-title":"Adrenocortical carcinoma: a practical guide for clinicians","author":"Fassnacht","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070905473546700_bib71","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ecl.2015.02.008","article-title":"Surgical management of adrenocortical carcinoma","volume":"44","author":"Fernandez Ranvier","year":"2015","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2026070905473546700_bib72","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","article-title":"Cushing\u2019s syndrome","volume":"402","author":"Gadelha","year":"2023","journal-title":"Lancet"},{"key":"2026070905473546700_bib73","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s10637-013-0013-1","article-title":"Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer","volume":"31","author":"Ganesan","year":"2013","journal-title":"Invest New Drugs"},{"key":"2026070905473546700_bib74","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1200\/jco.2014.32.15_suppl.4588","article-title":"Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03","volume":"32","author":"Garc\u00eda-Donas","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026070905473546700_bib75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.surg.2011.09.030","article-title":"Recommendation for standardized surgical management of primary adrenocortical carcinoma","volume":"152","author":"Gaujoux","year":"2012","journal-title":"Surgery"},{"key":"2026070905473546700_bib76","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/bjs.10414","article-title":"European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma","volume":"104","author":"Gaujoux","year":"2017","journal-title":"Br J Surg"},{"key":"2026070905473546700_bib77","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jviscsurg.2017.06.010","article-title":"Surgical treatment of adrenal carcinoma","volume":"154","author":"Gaujoux","year":"2017","journal-title":"J Visc Surg"},{"key":"2026070905473546700_bib78","doi-asserted-by":"crossref","first-page":"497.e1","DOI":"10.1016\/j.clgc.2022.04.011","article-title":"Association of surgical approach with treatment burden, oncological effectiveness, and perioperative morbidity in adrenocortical carcinoma","volume":"20","author":"Ginsburg","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2026070905473546700_bib79","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/1078-0432.CCR-08-1067","article-title":"Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling","volume":"15","author":"Giordano","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026070905473546700_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2024.42.4_suppl.1","article-title":"Cabozantinib plus atezolizumab in locally advanced\/metastatic adrenocortical carcinoma: results from a multi-cohort basket phase II trial, CABATEN\/GETNE-T1914","volume":"42","author":"Grande","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070905473546700_bib81","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1210\/jc.2012-2367","article-title":"A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma","volume":"98","author":"Habra","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib82","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J ImmunoTherapy Cancer"},{"key":"2026070905473546700_bib83","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1210\/jc.2011-2765","article-title":"[131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma","volume":"97","author":"Hahner","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib84","doi-asserted-by":"crossref","first-page":"E1348","DOI":"10.1210\/clinem\/dgab895","article-title":"Targeting 11-beta hydroxylase with [131I]IMAZA: a novel approach for the treatment of advanced adrenocortical carcinoma","volume":"107","author":"Hahner","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib85","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","article-title":"Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma","volume":"65","author":"Haluska","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026070905473546700_bib86","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13118","article-title":"The diagnosis and management of Cushing\u2019s syndrome in pregnancy","volume":"34","author":"Hamblin","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"2026070905473546700_bib186","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1210\/js.2019-00305","article-title":"Response to immunotherapy in combination with mitotane in patients with metastatic adrenocortical cancer","volume":"3","author":"Head","year":"2019","journal-title":"J Endocr Soc"},{"key":"2026070905473546700_bib87","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors","volume":"102","author":"Henning","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib88","doi-asserted-by":"crossref","first-page":"E476","DOI":"10.1210\/jc.2011-1982","article-title":"TP53 germline mutations in adult patients with adrenocortical carcinoma","volume":"97","author":"Herrmann","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib89","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/PPO.0b013e31829e3221","article-title":"Role of radiotherapy in adrenocortical carcinoma","volume":"19","author":"Ho","year":"2013","journal-title":"Cancer J"},{"key":"2026070905473546700_bib90","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1245\/s10434-020-08454-1","article-title":"Minimally invasive versus open adrenalectomy in patients with adrenocortical carcinoma: a meta-analysis","volume":"27","author":"Hu","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2026070905473546700_bib91","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1677\/ERC-07-0045","article-title":"The optimal imaging of adrenal tumours: a comparison of different methods","volume":"14","author":"Ilias","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"2026070905473546700_bib92","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MED.0000000000000626","article-title":"Approach to patients with European Network for the study of adrenal tumor stages I and II adrenocortical carcinomas","volume":"28","author":"Kastelan","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026070905473546700_bib93","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.soc.2022.10.005","article-title":"Adrenocortical carcinoma: role of adjuvant and neoadjuvant therapy","volume":"32","author":"Kenney","year":"2023","journal-title":"Surg Oncol Clin N Am"},{"key":"2026070905473546700_bib94","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in The Netherlands since 1993","volume":"49","author":"Kerkhofs","year":"2013","journal-title":"Eur J Cancer"},{"key":"2026070905473546700_bib95","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1385\/MO:21:2:167","article-title":"Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer","volume":"21","author":"Khan","year":"2004","journal-title":"Med Oncol"},{"key":"2026070905473546700_bib96","doi-asserted-by":"crossref","DOI":"10.1177\/20363613231160699","article-title":"Treatment outcomes of adjuvant radiotherapy in adrenocortical carcinoma \u2013 a 13-years experience from a tertiary care centre","volume":"15","author":"Khosla","year":"2023","journal-title":"Rare Tumors"},{"key":"2026070905473546700_bib97","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41416-021-01513-8","article-title":"Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study","volume":"125","author":"Kimpel","year":"2021","journal-title":"Br J Cancer"},{"key":"2026070905473546700_bib98","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/metabo14010020","article-title":"Early detection of recurrence and progress using serum steroid profiling by LC-MS\/MS in patients with adrenocortical carcinoma","volume":"14","author":"Kimpel","year":"2023","journal-title":"Metabolites"},{"key":"2026070905473546700_bib99","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/cancers16040706","article-title":"The value of local therapies in advanced adrenocortical carcinoma","volume":"16","author":"Kimpel","year":"2024","journal-title":"Cancers"},{"key":"2026070905473546700_bib100","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1908771","article-title":"Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538","volume":"10","author":"Klein","year":"2021","journal-title":"OncoImmunology"},{"key":"2026070905473546700_bib101","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"2026070905473546700_bib102","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1073\/pnas.1508113112","article-title":"Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia","volume":"112","author":"Koo","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070905473546700_bib103","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin Endocrinol"},{"key":"2026070905473546700_bib104","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4174\/astr.2024.107.4.187","article-title":"Early stage adrenocortical carcinoma-what contributes to poor prognosis after adrenalectomy? A retrospective cohort study","volume":"107","author":"Kwon","year":"2024","journal-title":"Ann Surg Treat Res"},{"key":"2026070905473546700_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100422","article-title":"Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma","volume":"7","author":"Lagan\u00e0","year":"2022","journal-title":"ESMO Open"},{"key":"2026070905473546700_bib107","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026070905473546700_bib108","doi-asserted-by":"crossref","first-page":"43016","DOI":"10.18632\/oncotarget.5513","article-title":"Inhibition of the Tcf\/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis","volume":"6","author":"Leal","year":"2015","journal-title":"Oncotarget"},{"key":"2026070905473546700_bib109","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1530\/EJE-09-1096","article-title":"Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?","volume":"162","author":"Leboulleux","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib110","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/bloodadvances.2019000757","article-title":"Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"4","author":"Lee","year":"2020","journal-title":"Blood Adv"},{"key":"2026070905473546700_bib111","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","article-title":"The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial","volume":"5","author":"Lerario","year":"2014","journal-title":"Horm Cancer"},{"key":"2026070905473546700_bib112","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fendo.2020.00219","article-title":"Targeted gene expression profile reveals CDK4 as therapeutic target for selected patients with adrenocortical carcinoma","volume":"11","author":"Liang","year":"2020","journal-title":"Front Endocrinol"},{"key":"2026070905473546700_bib113","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann Oncol"},{"key":"2026070905473546700_bib114","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/RLU.0000000000004593","article-title":"Positive correlation between 18 F-FDG uptake and tumor-proliferating antigen Ki-67 expression in adrenocortical carcinomas","volume":"48","author":"Lib\u00e9","year":"2023","journal-title":"Clin Nucl Med"},{"key":"2026070905473546700_bib115","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.surg.2014.08.047","article-title":"Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease","volume":"156","author":"Livhits","year":"2014","journal-title":"Surgery"},{"key":"2026070905473546700_bib116","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.surg.2012.08.014","article-title":"Open versus endoscopic adrenalectomy in the treatment of localized (stage I\/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey","volume":"152","author":"Lombardi","year":"2012","journal-title":"Surgery"},{"key":"2026070905473546700_bib117","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1677\/ERC-09-0170","article-title":"Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model","volume":"17","author":"Luconi","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"2026070905473546700_bib187","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.21037\/qims-20-875","article-title":"Role of 18F-FDG PET\/CT in the differential diagnosis of primary benign and malignant unilateral adrenal tumors","volume":"11","author":"Ma","year":"2021","journal-title":"Quant Imaging Med Surg"},{"key":"2026070905473546700_bib118","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1530\/EJE-17-1056","article-title":"Diagnostic accuracy of computed tomography to identify adenomas among adrenal incidentalomas in an endocrinological population","volume":"178","author":"Marty","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib119","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/bju.13618","article-title":"Surgical quality of minimally invasive adrenalectomy for adrenocortical carcinoma: a contemporary analysis using the National Cancer Database","volume":"119","author":"Maurice","year":"2017","journal-title":"BJU Int"},{"key":"2026070905473546700_bib120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/ls-21-24","article-title":"Retroperitoneoscopic adrenalectomy: indications and technical considerations","volume":"6","author":"McCoy","year":"2022","journal-title":"Laparosc Surg"},{"key":"2026070905473546700_bib121","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter , phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"key":"2026070905473546700_bib122","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1174119","article-title":"Medical treatment of Cushing\u2019s disease with concurrent diabetes mellitus","volume":"14","author":"Mehlich","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026070905473546700_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjsurg.2024.115999","article-title":"Survival impact of treatment utilization and margin status after resection of adrenocortical carcinoma","volume":"239","author":"Memeh","year":"2025","journal-title":"Am J Surg"},{"key":"2026070905473546700_bib125","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12022-018-9525-8","article-title":"Immunohistochemical biomarkers of adrenal cortical neoplasms","volume":"29","author":"Mete","year":"2018","journal-title":"Endocr Pathol"},{"key":"2026070905473546700_bib126","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12022-022-09710-8","article-title":"Overview of the 2022 WHO classification of adrenal cortical tumors","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026070905473546700_bib127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/ph17010025","article-title":"Radiopharmaceuticals for treatment of adrenocortical carcinoma","volume":"17","author":"Michalski","year":"2023","journal-title":"Pharmaceuticals"},{"key":"2026070905473546700_bib128","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s40618-022-01836-0","article-title":"Tumour size in adrenal tumours: its importance in the indication of adrenalectomy and in surgical outcomes-a single-centre experience","volume":"45","author":"M\u00ednguez Ojeda","year":"2022","journal-title":"J Endocrinol Investig"},{"key":"2026070905473546700_bib129","article-title":"Cushing syndrome due to adrenocortical carcinoma during pregnancy","volume":"1","author":"Morris","year":"2023","journal-title":"JCEM Case Rep"},{"key":"2026070905473546700_bib130","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/bjc.2013.46","article-title":"Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma","volume":"108","author":"Naing","year":"2013","journal-title":"Br J Cancer"},{"key":"2026070905473546700_bib131","doi-asserted-by":"crossref","first-page":"e198898","DOI":"10.1001\/jamanetworkopen.2019.8898","article-title":"Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral pheochromocytomas undergoing total adrenalectomy vs cortical-sparing adrenalectomy","volume":"2","author":"Neumann","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026070905473546700_bib132","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of cushing\u2019s syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib133","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"O\u2019Sullivan","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib134","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12672-019-00367-0","article-title":"Metastatic adrenocortical carcinoma: a single institutional experience","volume":"10","author":"Owen","year":"2019","journal-title":"Horm Cancer"},{"key":"2026070905473546700_bib136","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/bjc.2017.330","article-title":"A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours","volume":"117","author":"Papadopoulos","year":"2017","journal-title":"Br J Cancer"},{"key":"2026070905473546700_bib137","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1530\/EJE-14-0916","article-title":"Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry","volume":"172","author":"Petersenn","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib138","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/j.seminoncol.2016.08.007","article-title":"Genetic predisposition to endocrine tumors: diagnosis, surveillance and challenges in care","volume":"43","author":"Petr","year":"2016","journal-title":"Semin Oncol"},{"key":"2026070905473546700_bib139","doi-asserted-by":"crossref","first-page":"R271","DOI":"10.1530\/ERC-21-0208","article-title":"The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer","volume":"28","author":"Pittaway","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"2026070905473546700_bib140","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/14737140.2018.1510325","article-title":"Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options","volume":"18","author":"Puglisi","year":"2018","journal-title":"Expet Rev Anticancer Ther"},{"key":"2026070905473546700_bib141","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ecl.2018.02.003","article-title":"Adrenocortical carcinoma with hypercortisolism","volume":"47","author":"Puglisi","year":"2018","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2026070905473546700_bib142","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11154-022-09769-y","article-title":"Pregnancy in patients with adrenocortical carcinoma: a case-based discussion","volume":"24","author":"Puglisi","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"key":"2026070905473546700_bib143","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1210\/clinem\/dgad199","article-title":"New findings on presentation and outcome of patients with adrenocortical cancer: results from a National Cohort Study","volume":"108","author":"Puglisi","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib144","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1210\/jc.2007-2564","article-title":"Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine","volume":"93","author":"Quinkler","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026070905473546700_bib146","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2012.48.0988","article-title":"Adrenocortical carcinoma is a lynch syndrome-associated cancer","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070905473546700_bib147","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/ejendo\/lvad054","article-title":"Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study","volume":"188","author":"Remde","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib148","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1200\/JCO.20.02871","article-title":"Treatment of pediatric adrenocortical carcinoma with surgery, retroperitoneal lymph node dissection, and chemotherapy: the Children\u2019s Oncology Group ARAR0332 Protocol","volume":"39","author":"Rodriguez-Galindo","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070905473546700_bib149","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12020-024-04042-5","article-title":"[18F]FDG-PET\/CT in adrenal lesions: diagnostic performance in different clinical settings","volume":"87","author":"Romanisio","year":"2024","journal-title":"Endocrine"},{"key":"2026070905473546700_bib150","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.3390\/cancers14112730","article-title":"Loco-regional therapies in oligometastatic adrenocortical carcinoma","volume":"14","author":"Roux","year":"2022","journal-title":"Cancers"},{"key":"2026070905473546700_bib151","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijrobp.2015.01.007","article-title":"Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma","volume":"92","author":"Sabolch","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026070905473546700_bib152","doi-asserted-by":"crossref","first-page":"15527","DOI":"10.1200\/jco.2007.25.18_suppl.15527","article-title":"A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC)","volume":"25","author":"Samnotra","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026070905473546700_bib153","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1245\/s10434-022-12725-4","article-title":"Mitotane with or without cisplatin and etoposide for patients with a high risk of recurrence in stages 1-3 adrenocortical cancer after surgery","volume":"30","author":"Sarvestani","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2026070905473546700_bib154","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1530\/EJE-21-0650","article-title":"Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant adrenal masses","volume":"186","author":"Schloetelburg","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib155","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1007\/s00259-024-06800-z","article-title":"Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma","volume":"51","author":"Schloetelburg","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070905473546700_bib156","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2214\/AJR.15.14467","article-title":"Imaging features of various adrenal neoplastic lesions on radiologic and nuclear medicine imaging","volume":"205","author":"Shin","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"2026070905473546700_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101408","article-title":"Surgery for adrenocortical carcinoma: when and how?","volume":"34","author":"Sinclair","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"2026070905473546700_bib158","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1021\/acs.molpharmaceut.9b00542","article-title":"111In- and 225Ac-labeled cixutumumab for imaging and \u03b1-particle radiotherapy of IGF-1R positive triple-negative breast cancer","volume":"16","author":"Solomon","year":"2019","journal-title":"Mol Pharm"},{"key":"2026070905473546700_bib159","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75279-z","article-title":"Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer","volume":"10","author":"Solomon","year":"2020","journal-title":"Sci Rep"},{"key":"2026070905473546700_bib160","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"2026070905473546700_bib161","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ajo.13793","article-title":"Diverse presentations of Cushing\u2019s syndrome during pregnancy \u2013 a case series","volume":"64","author":"Stoinis","year":"2024","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2026070905473546700_bib135","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.62347\/QKWF9884","article-title":"The effect of adjuvant mitotane therapy of the adrenocortical carcinoma on the endometrium and its clinical consequences in menstruating women. Literature review and authors\u2019 own experiences","volume":"14","author":"Szkodziak","year":"2024","journal-title":"Am J Cancer Res"},{"key":"2026070905473546700_bib162","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-21-1008","article-title":"Efficacy and tolerance of osilodrostat in patients with Cushing\u2019s syndrome due to adrenocortical carcinomas","volume":"186","author":"Tabarin","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib163","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070905473546700_bib164","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1210\/jc.2012-2839","article-title":"Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature","volume":"98","author":"Tripto-Shkolnik","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905473546700_bib165","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12020-022-03075-y","article-title":"Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen","volume":"77","author":"Turla","year":"2022","journal-title":"Endocrine"},{"key":"2026070905473546700_bib166","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/bjc.2013.229","article-title":"Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study","volume":"108","author":"Urup","year":"2013","journal-title":"Br J Cancer"},{"key":"2026070905473546700_bib167","first-page":"377","article-title":"CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma","volume":"67","author":"Van Slooten","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"2026070905473546700_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2021.101490","article-title":"Updates in adrenal steroidogenesis inhibitors for Cushing\u2019s syndrome \u2013 a practical guide","volume":"35","author":"Varlamov","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"2026070905473546700_bib169","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1007\/s00330-020-07019-w","article-title":"Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation","volume":"30","author":"Veltri","year":"2020","journal-title":"Eur Radiol"},{"key":"2026070905473546700_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117301","article-title":"Simplified urinary steroid profiling by LC-MS as diagnostic tool for malignancy in adrenocortical tumors","volume":"543","author":"Vogg","year":"2023","journal-title":"Clin Chim Acta"},{"key":"2026070905473546700_bib171","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","article-title":"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov"},{"key":"2026070905473546700_bib172","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41418-023-01122-3","article-title":"The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells","volume":"30","author":"Wang","year":"2023","journal-title":"Cell Death Differ"},{"key":"2026070905473546700_bib173","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/pbc.24605","article-title":"Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children\u2019s Oncology Group","volume":"61","author":"Weigel","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2026070905473546700_bib174","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000478-198903000-00004","article-title":"Pathologic features of prognostic significance in adrenocortical carcinoma","volume":"13","author":"Weiss","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"2026070905473546700_bib175","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/00000478-200307000-00001","article-title":"Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients","volume":"27","author":"Wieneke","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"2026070905473546700_bib176","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R","article-title":"Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group study","volume":"88","author":"Williamson","year":"2000","journal-title":"Cancer"},{"key":"2026070905473546700_bib177","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1097\/RLU.0000000000001112","article-title":"Molecular imaging in the management of adrenocortical cancer: a systematic review","volume":"41","author":"Wong","year":"2016","journal-title":"Clin Nucl Med"},{"key":"2026070905473546700_bib178","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.11084","article-title":"Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases","volume":"97","author":"Wood","year":"2003","journal-title":"Cancer"},{"key":"2026070905473546700_bib179","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/EJE-09-0804","article-title":"Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma","volume":"162","author":"Wortmann","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"2026070905473546700_bib180","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.surg.2018.07.026","article-title":"Laparoscopic versus open adrenalectomy for localized (stage 1\/2) adrenocortical carcinoma: experience at a single, high-volumecenter","volume":"164","author":"Wu","year":"2018","journal-title":"Surgery"},{"key":"2026070905473546700_bib181","article-title":"Challenges in the postsurgical recovery of cushing syndrome: glucocorticoid withdrawal syndrome","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Endocrinol"},{"key":"2026070905473546700_bib182","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"2026070905473546700_bib183","doi-asserted-by":"crossref","first-page":"22825","DOI":"10.18632\/oncotarget.15221","article-title":"Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"2026070905473546700_bib184","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-020-01533-3","article-title":"Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis","volume":"15","author":"Zhu","year":"2020","journal-title":"Radiat Oncol"},{"key":"2026070905473546700_bib185","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54661-9","article-title":"Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat Commun"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/5\/ERC-25-0034.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/5\/ERC-25-0034.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0034\/145585\/erc-25-0034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0034\/145585\/erc-25-0034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:48:02Z","timestamp":1783590482000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/5\/e250034\/26025\/Spanish-consensus-on-the-diagnosis-and-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":188,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0034","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"article-number":"e250034"}}